Research study Program year 2025 Source: CMS Open Payments

Observation Priority E Short - Lebrikizumab - Atopic Dermatitis

Research payments

$628,635

43 payments

Through program year 2025, $628,635 in research payments was reported against Observation Priority E Short - Lebrikizumab - Atopic Dermatitis, across 43 payments, paid by Eli Lilly and Company.

Paid by: Eli Lilly and Company
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$628,635	43

Breakdown

Who paid Research payments · program year 2025

Eli Lilly and Company $628,635 43 payments

Who received the money Research payments · program year 2025

Advanced Dermatology Of Sc, Pc Organisation paid for research $71,006 1 payment
Granite State Dermatology Organisation paid for research $69,351 1 payment
Johns Hopkins University Organisation paid for research $32,525 1 payment
Dba Miami Dermatology & Laser Research LLC Organisation paid for research $31,872 1 payment
The Derm Institute Of West Michigan Organisation paid for research $31,290 1 payment
Allergy And Asthma Specialists Psc Organisation paid for research $24,051 1 payment
Driven Research LLC Organisation paid for research $23,705 1 payment
Alliance For Multispecialty Research Lls Organisation paid for research $23,350 2 payments
Dermatology And Skin Cancer Specialists LLC Organisation paid for research $21,395 1 payment
Florida Center For Dermatology, PA Organisation paid for research $18,531 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.